Omeros Corporation (0KBU.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:13PM BST
| Previous close | 3.3500 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,368 |
| Market cap | 1.445M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 3.1390 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
Business WireOmeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include:
© 2024 Yahoo. All rights reserved.